Using antisense oligonucleotides targeting YB1 (YB1-ASOA) can specifically inhibit YB-1 protein expression in tumor vascular endothelial cells, thereby downregulating the Bcl-xL/VEGFR2 and Bcl-xL/Tie signaling axes, inhibiting these two key angiogenic regulatory factors, reducing angiogenesis, and thereby inhibiting tumor growth, which also indirectly illustrates YB1’s role in promoting cancer vascular growth (61) (Figure 3). The gene discussed is KDR; the disease is neoplasm.